Technical Analysis for SYBX - Synlogic, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -5.17% | |
| Stochastic Buy Signal | Bullish | -5.17% | |
| Gapped Up | Strength | -5.17% | |
| Oversold Stochastic | Weakness | -5.17% | |
| New 52 Week Closing Low | Bearish | 0.74% | |
| Lower Bollinger Band Walk | Weakness | 0.74% | |
| Oversold Stochastic | Weakness | 0.74% | |
| Lower Bollinger Band Walk | Weakness | 0.01% | |
| Lower Bollinger Band Touch | Weakness | 0.01% | |
| Oversold Stochastic | Weakness | 0.01% |
| Alert | Time |
|---|---|
| Down 5% | 1 minute ago |
| Down 3% | 1 minute ago |
| Fell Below Previous Day's Low | 1 minute ago |
| Down 2 % | 1 minute ago |
| Fell Below 10 DMA | 1 minute ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Synlogic, Inc. Description
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Metabolism Genetic Diseases Synthetic Biology Inborn Errors Of Metabolism Rare Genetic Disease Rare Genetic Diseases Newborn Screening Intellectual Disability Phenylketonuria Pku Urea Cycle
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.1181 |
| 52 Week Low | 1.22 |
| Average Volume | 10,806 |
| 200-Day Moving Average | 1.64 |
| 50-Day Moving Average | 1.45 |
| 20-Day Moving Average | 1.42 |
| 10-Day Moving Average | 1.41 |
| Average True Range | 0.08 |
| RSI (14) | 52.38 |
| ADX | 37.92 |
| +DI | 24.19 |
| -DI | 8.94 |
| Chandelier Exit (Long, 3 ATRs) | 1.42 |
| Chandelier Exit (Short, 3 ATRs) | 1.59 |
| Upper Bollinger Bands | 1.49 |
| Lower Bollinger Band | 1.36 |
| Percent B (%b) | 0.67 |
| BandWidth | 9.07 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.52 | ||||
| Resistance 3 (R3) | 1.51 | 1.48 | 1.51 | ||
| Resistance 2 (R2) | 1.48 | 1.46 | 1.48 | 1.50 | |
| Resistance 1 (R1) | 1.46 | 1.45 | 1.47 | 1.47 | 1.50 |
| Pivot Point | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
| Support 1 (S1) | 1.41 | 1.41 | 1.42 | 1.42 | 1.39 |
| Support 2 (S2) | 1.38 | 1.40 | 1.38 | 1.39 | |
| Support 3 (S3) | 1.36 | 1.38 | 1.38 | ||
| Support 4 (S4) | 1.37 |
